Ozempic does something unexpected to the brain’s hunger neurons
Yale researchers have discovered that GLP-1 medications like Ozempic work by recruiting hunger-stimulating neurons in the brain to help maintain fat loss, rather than just suppressing appetite. This finding challenges previous assumptions about how these drugs affect brain circuits.
Why it matters
Understanding the specific neurological mechanisms of weight-loss drugs could lead to the development of more effective and targeted obesity treatments.
For decades, medications for obesity typically delivered only modest reductions in body weight. That changed with the arrival of Ozempic and other GLP-1 therapies, which can produce sustained weight loss of 10 to 15% or more. Yet despite their remarkable effectiveness, scientists still do not fully understand what these medications are doing inside the brain.
New research from Yale has now uncovered an unexpected mechanism that challenges a long-standing view of the brain circuits involved in hunger and weight control. Scientists had generally thought that agouti-related peptide (AgRP) neurons, which are well known for stimulating hunger, worked mainly against weight loss. The new findings suggest something very different. During treatment with GLP-1 drugs such as Ozempic, these neurons appear to be recruited to help maintain fat loss.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in